Abstract
Goals of work
Chemotherapy plays a major role in the treatment of cancer. However, it is sometimes thought of as being taken too far, being used in many cases close to death. The purpose of this study is to determine the proximity of chemotherapy use to the patient’s death in our hospital.
Materials and methods
This study comprised the analysis of the charts of 1,064 patients aged over 16 years with solid tumors who died in 2002 and were treated at the Porto Section of the Portuguese Institute of Oncology.
Main results
Four hundred ten of the 1,064 patients (39%) underwent chemotherapy. Fifty-two percent of those that underwent chemotherapy did so in the last 6 months of their lives, 31% in the last 3 months, 13% in the last month, and 3% in the last week. In the context of the total cohort of 1,064, the percentages of those that underwent chemotherapy was 20, 12, 5, and 1%, respectively. By multivariate analysis, age <65 years, breast and lung cancers, and metastases were positively associated with chemotherapy; kidney cancer and comorbidity were associated with a lower probability of undergoing chemotherapy. Three hundred sixty-one patients (34%) were admitted to the palliative care unit of the hospital.
Conclusion
It was concluded that in this hospital, chemotherapy is not used as close to death as often as most professionals feel and the literature reports. There are various possible explanations for this discrepancy; one of them may be the influence of health care systems. It would be useful to see what is happening in other countries with different health care systems.
Similar content being viewed by others
References
Aragon-Ching JB, Cohn JB, Cohn A (2003) Chemotherapy at the end of life. Proc Am Soc Clin Oncol 22(abst 3119)
Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS (2003) Chemotherapy use among Medicaire beneficiaries at the end of life. Ann Intern Med 138:639–643
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22:315–321
Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496
Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC (2000) Who gets chemotherapy for metastatic lung cancer. Chest 117:1239–1246
Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21:3488–3494
Hurria A, Naeim A, Elkin E, Limaye S, Grover A, Hudis C, Pearce C, Robson M (2007) Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. Crit Rev Oncol Hematol 61:255–260
Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274
Slevin ML, Stubbs I, Plant HJ et al (1990) Attitudes to chemotherapy: comparative views of patients with cancer with those of doctors, nurses, and general public. BMJ 300:1458–1460
Yellen SB, Cella DF (1995) Someone to live for: social well-being, parenthood status and decision-making in oncology. J Clin Oncol 13:1255–1264
Jirillo A, Boscaro M, Passeto LM, Monfardini S (2005) Chemotherapy at the end of life: an open question. Tumori 91:104–105
Glare P, Virik K, Jones M et al (2003) A systematic review of physicians’ predictions in terminally ill cancer patients. BMJ 327:195–200
Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, Priest K (1995) Symptom relief with MVPP (mitomycin C, vinblastine and cisplatina) chemotherapy in advanced non-small-cell lung cancer. BJC 71:366–370
Cullen MH, Billingham LJ, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17:3188–3194
Cunningham D, Pyrhönen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418
Burris HA, Moore MJ, Andersen MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
Wan GJ, Counte MA, Cella DF (1997) The influence of personal expectations on cancer patients’ report of health-related quality of life. Psycho-Oncol 6:1–11
Graffar M (1956) Une méthode de Classification Social d’échantillon de la population. Courier 6:455–459
Acknowledgements
This work was supported in part by the North Portugal Section of the Portuguese League against Cancer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gonçalves, J.F., Goyanes, C. Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer 16, 321–327 (2008). https://doi.org/10.1007/s00520-007-0316-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-007-0316-x